524 related articles for article (PubMed ID: 23312990)
1. Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria.
Shim JH; Han S; Shin YM; Yu E; Park W; Kim KM; Lim YS; Lee HC
J Vasc Interv Radiol; 2013 Mar; 24(3):316-25. PubMed ID: 23312990
[TBL] [Abstract][Full Text] [Related]
2. Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation.
Dioguardi Burgio M; Ronot M; Bruno O; Francoz C; Paradis V; Castera L; Durand F; Soubrane O; Vilgrain V
Liver Transpl; 2016 Nov; 22(11):1491-1500. PubMed ID: 27543821
[TBL] [Abstract][Full Text] [Related]
3. Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome.
Vandecaveye V; Michielsen K; De Keyzer F; Laleman W; Komuta M; Op de beeck K; Roskams T; Nevens F; Verslype C; Maleux G
Radiology; 2014 Mar; 270(3):747-57. PubMed ID: 24475816
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
Gordic S; Corcuera-Solano I; Stueck A; Besa C; Argiriadi P; Guniganti P; King M; Kihira S; Babb J; Thung S; Taouli B
J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
[TBL] [Abstract][Full Text] [Related]
5. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
Niessen C; Unterpaintner E; Goessmann H; Schlitt HJ; Mueller-Schilling M; Wohlgemuth WA; Stroszczynski C; Wiggermann P
J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
[TBL] [Abstract][Full Text] [Related]
6. Intraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.
Wang Z; Chen R; Duran R; Zhao Y; Yenokyan G; Chapiro J; Schernthaner R; Radaelli A; Lin M; Geschwind JF
Cardiovasc Intervent Radiol; 2015 Dec; 38(6):1548-56. PubMed ID: 26001366
[TBL] [Abstract][Full Text] [Related]
7. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS
J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
[TBL] [Abstract][Full Text] [Related]
9. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
[TBL] [Abstract][Full Text] [Related]
10. MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Kloeckner R; Otto G; Biesterfeld S; Oberholzer K; Dueber C; Pitton MB
Cardiovasc Intervent Radiol; 2010 Jun; 33(3):532-40. PubMed ID: 19847482
[TBL] [Abstract][Full Text] [Related]
11. Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients.
Song MJ; Park CH; Kim JD; Kim HY; Bae SH; Choi JY; Yoon SK; Chun HJ; Choi BG; Lee HG
Eur J Gastroenterol Hepatol; 2011 Jun; 23(6):521-7. PubMed ID: 21537127
[TBL] [Abstract][Full Text] [Related]
12. C-arm Lipiodol CT in transcatheter arterial chemoembolization for small hepatocellular carcinoma.
Li JJ; Zheng JS; Cui SC; Cui XW; Hu CX; Fang D; Ye LC
World J Gastroenterol; 2015 Mar; 21(10):3035-40. PubMed ID: 25780303
[TBL] [Abstract][Full Text] [Related]
13. Transarterial Chemoembolization of Hepatocellular Carcinoma Using Radiopaque Drug-Eluting Embolics: How to Pursue Periprocedural Cross-Sectional Imaging?
Ruff C; Grözinger G; Syha R; Elser S; Partovi S; Bitzer M; Horger M; Nikolaou K; Grosse U
J Vasc Interv Radiol; 2019 Mar; 30(3):380-389.e4. PubMed ID: 30819480
[TBL] [Abstract][Full Text] [Related]
14. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).
Prajapati HJ; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
Ann Oncol; 2013 Apr; 24(4):965-73. PubMed ID: 23223331
[TBL] [Abstract][Full Text] [Related]
15. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation.
Nicolini D; Agostini A; Montalti R; Mocchegiani F; Mincarelli C; Mandolesi A; Robertson NL; Candelari R; Giovagnoni A; Vivarelli M
World J Gastroenterol; 2017 May; 23(20):3690-3701. PubMed ID: 28611522
[TBL] [Abstract][Full Text] [Related]
16. Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma: usefulness of contrast saturation features on cone-beam computed tomography imaging for predicting short-term tumor response.
Suk Oh J; Jong Chun H; Gil Choi B; Giu Lee H
J Vasc Interv Radiol; 2013 Apr; 24(4):483-9. PubMed ID: 23452553
[TBL] [Abstract][Full Text] [Related]
17. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy.
Bonekamp S; Halappa VG; Geschwind JF; Li Z; Corona-Villalobos CP; Reyes D; Bhagat N; Cosgrove DP; Pawlik TM; Mezey E; Eng J; Kamel IR
Radiology; 2013 Aug; 268(2):431-9. PubMed ID: 23616632
[TBL] [Abstract][Full Text] [Related]
18. Lipiodol retention pattern assessed by cone beam computed tomography during conventional transarterial chemoembolization of hepatocellular carcinoma: accuracy and correlation with response.
Hu J; Maybody M; Cao G; Wang X; Chen H; Zhu X; Yang R; Wang X
Cancer Imaging; 2016 Oct; 16(1):32. PubMed ID: 27716376
[TBL] [Abstract][Full Text] [Related]
19. Baseline and Early MR Apparent Diffusion Coefficient Quantification as a Predictor of Response of Unresectable Hepatocellular Carcinoma to Doxorubicin Drug-Eluting Bead Chemoembolization.
Kokabi N; Ludwig JM; Camacho JC; Xing M; Mittal PK; Kim HS
J Vasc Interv Radiol; 2015 Dec; 26(12):1777-86. PubMed ID: 26603497
[TBL] [Abstract][Full Text] [Related]
20. EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.
Liu L; Wang W; Chen H; Zhao Y; Bai W; Yin Z; He C; Jia J; Yang M; Xia J; Fan D; Han G
Clin Cancer Res; 2014 Mar; 20(6):1623-31. PubMed ID: 24493832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]